A5051652718- Cardiomyopathy and Myosin Studies
- Cardiovascular Function and Risk Factors
- Cardiovascular Effects of Exercise
- Cardiac Structural Anomalies and Repair
- Cardiac pacing and defibrillation studies
- Congenital Heart Disease Studies
- Viral Infections and Immunology Research
- Cardiac Arrhythmias and Treatments
- Cardiac Valve Diseases and Treatments
- Takotsubo Cardiomyopathy and Associated Phenomena
- Cardiac electrophysiology and arrhythmias
- Cardiac Imaging and Diagnostics
- Congenital heart defects research
- Atrial Fibrillation Management and Outcomes
- Coronary Artery Anomalies
- Cardiovascular Disease and Adiposity
- Cardiovascular Issues in Pregnancy
- Cardiac Arrest and Resuscitation
- Pericarditis and Cardiac Tamponade
- Trypanosoma species research and implications
- Williams Syndrome Research
- Innovation Policy and R&D
- Cardiac tumors and thrombi
- Infective Endocarditis Diagnosis and Management
- Advanced battery technologies research
NYU Langone Health
2016-2025
Diabetes & Endocrine Associates
2019-2025
New York University
2015-2025
Sequoia (United States)
2024
SEQUOIA (Italy)
2024
Cleveland Clinic
2023
Hinge Health
2023
Lahey Medical Center
2023
Oregon Health & Science University
2023
Minneapolis Heart Institute Foundation
2005-2018
Recently, the implantable cardioverter-defibrillator (ICD) has been promoted for prevention of sudden death in hypertrophic cardiomyopathy (HCM). However, effectiveness and appropriate selection patients this therapy is incompletely resolved.To study relationship between clinical risk profile incidence efficacy ICD intervention HCM.Multicenter registry ICDs implanted 1986 2003 506 unrelated with HCM. Patients were judged to be at high death; had received ICDs; underwent evaluation 42...
Patients with nonobstructive hypertrophic cardiomyopathy (nHCM) often experience a high burden of symptoms; however, there are no proven pharmacological therapies. By altering the contractile mechanics cardiomyocyte, myosin inhibitors have potential to modify pathophysiology and improve symptoms associated HCM.MAVERICK-HCM (Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy) explored safety efficacy mavacamten, first-in-class reversible inhibitor...
Background This open-label phase 2 trial evaluated the safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). Methods Patients symptomatic nHCM (left ventricular outflow tract obstruction gradient ≤30 mmHg, left ejection fraction [LVEF] ≥60%, N-terminal pro-B-type natriuretic peptide [NT-proBNP] >300 pg/mL) received 5–20 mg once daily (doses adjusted according to echocardiographic LVEF) for 10 weeks. Results 41 were enrolled (mean ± SD age 56 16...
Background Disopyramide is used to treat heart failure symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM) known medium‐term efficacy and safety, while long‐term outcomes are unknown. Methods Results A total of 92 consecutive symptomatic HCM peak left ventricular outflow tract gradients ≥30 mm Hg at rest or provocation who were maintained on disopyramide for ≥5 years 2 dedicated centers included: patients; mean age, 62.5 years; 54% women; treated median 7.2 (left wall...
Background— Nonobstructive hypertrophy localized to the cardiac apex is an uncommon morphological variant of hypertrophic cardiomyopathy (HCM) that often further distinguished by distinct giant negative T waves and a benign clinical course. The genetic relationship between HCM with typical morphology versus isolated apical incompletely understood. Methods Results— Genetic cause was investigated in 15 probands DNA sequence analyses 9 sarcomere protein genes 3 other ( GLA , PRKAG2 LAMP2 )...
There is controversy about preferred methods to relieve obstruction in hypertrophic cardiomyopathy patients still symptomatic after β-blockade or verapamil.Of 737 prospectively registered at our institution, 299 (41%) required further therapy for limiting symptoms, rest gradient 61 ± 45, provoked 115 49 mm Hg, and followed up 4.8 years. Disopyramide was added 221 (74%) pharmacological control of symptoms achieved 141 (64%) patients. Overall, 138 (46%) had surgical relief (91% myectomy) 6...
Background— Sarcomere protein mutations in hypertrophic cardiomyopathy induce subtle cardiac structural changes before the development of left ventricular hypertrophy (LVH). We have proposed that myocardial crypts are part this phenotype and independently associated with presence sarcomere gene mutations. tested hypothesis genetic pre-LVH (genotype positive, LVH negative [G+LVH−]). Methods Results— A multicenter case–control study investigated 22 other cardiovascular magnetic resonance...
Background: Late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging (CMR) is believed to represent dense replacement fibrosis. It seen in ≈60% of adult patients with hypertrophic cardiomyopathy (HCM). However, the prevalence LGE children and adolescents HCM not well established. In addition, longitudinal studies describing development evolution pediatric are lacking. This study assesses prevalence, progression, clinical correlations with, or genetically predisposed to, HCM....
Purpose To evaluate myocardial strain and circumferential transmural difference (cTSD; the between epicardial endocardial strain) in a genotyped cohort with hypertrophic cardiomyopathy (HCM) to explore correlations cTSD other anatomic functional markers of disease status. Left ventricular (LV) dysfunction may indicate early preclinical HCM (sarcomere mutation carriers without LV hypertrophy). Cardiac MRI feature tracking be used sarcomere mutation. Materials Methods Participants their family...
Septal reduction therapy (SRT) in patients with intractable symptoms from obstructive hypertrophic cardiomyopathy (oHCM) is associated variable morbidity and mortality. The VALOR-HCM trial (A Study to Evaluate Mavacamten Adults Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Reduction Therapy) examined the effect of mavacamten on need SRT through week 32 oHCM.A double-blind randomized placebo-controlled multicenter at 19 US sites included oHCM maximal tolerated...